ASX:HMD HeraMED (HMD) Stock Price, News & Analysis → The only AI company to buy (From Porter & Company) (Ad) Free HMD Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume98,572 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get HeraMED alerts: Email Address Ad Porter & CompanyThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About HeraMED Stock (ASX:HMD)HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. It also provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus' heartbeat; and HeraCARE, a cloud-based remote maternity care platform. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is based in Netanya, Israel.Read More Ad Porter & CompanyThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. HMD Stock News HeadlinesApril 15, 2024 | finance.yahoo.comHeraMED Full Year 2023 Earnings: US$0.017 loss per share (vs US$0.023 loss in FY 2022)July 10, 2023 | msn.comCLOSING BELL: ASX sags to a 0.56pc drop, the precise opposite of this morning’s early gainsJune 14, 2023 | msn.comASX Health Stocks: All about closing deals this morning as HeraMED and Careteq sign new contractsMay 10, 2023 | msn.comASX Health Stocks: A good day for women’s healthcare with big news from HeraMED and EcofibreApril 8, 2023 | ca.finance.yahoo.comHeraMED Limited (HMD.AX)February 20, 2023 | msn.comASX Health Stocks: HeraMED is traveling smoothly in the US; Recce names Adelaide firm to run Phase1/2 trialDecember 9, 2022 | msn.comASX Small Caps Lunch Wrap: Who else is looking for a unicorn this morning?November 12, 2022 | finanznachrichten.dePlintron, Konic and HMD announce a strategic handset partnership to enhance customer experienceNovember 8, 2022 | msn.comASX Health Stocks: These three ASX biotechs get to strut their stuff with Bell Potter and Nature PortfolioJuly 18, 2022 | msn.comTop 10 at 10: Which ASX stocks are sailing and sinking today?August 12, 2021 | msn.comASX Tech Stocks: ESG platform Envirosuite (ASX:EVA) up 8.33% with plans to accelerate US growthJuly 22, 2021 | afr.comHeraMED LimitedSee More Headlines Receive HMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HeraMED and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:HMD CUSIPN/A CIKN/A Webwww.hera-med.com Phone61 8 6189 1155FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-270.58% Return on Assets-89.78% Debt Debt-to-Equity Ratio38.11 Current Ratio1.28 Quick Ratio2.83 Sales & Book Value Annual Sales$205,434.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow5.25 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares388,250,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.06 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Sivan SadanExecutive Vice PresidentMs. Anoushka GungadinCEO & DirectorMr. Cameron Jones C.A.CFO & Company SecretaryHenry JordanHead of Investor RelationsMr. Keith Koby BSEETMBA, President of North AmericaKey Competitors4DMedicalASX:4DXAdheriumASX:ADRAinosNASDAQ:AIMDWAllegra Medical TechnologiesASX:AMTAnalyticaASX:ALTView All CompetitorsInsidersDavid HintonBought 71,667 shares on 3/28/2024Total: $1,433.34 ($0.02/share)Ronald (Ron) WeinbergerSold 7,500,000 sharesTotal: $465,000.00 ($0.06/share) This page (ASX:HMD) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersNvidia’s Quiet $1 Trillion PivotWeiss RatingsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWrite this ticker symbol down…StocksToTradeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProBill Gates is all about this tiny $2 stockTimothy SykesBiden replacement revealed?Paradigm Press4 Cryptos BETTER than BitcoinTrue Market InsidersNo experience to confident trader, meet my student…Wealth Builders Institute Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HeraMED Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
